Degenerating intervertebral disc nucleus pulposus tissue (NP tissue)

The nucleus pulposus (NP) is the highly hydrated, gelatinous central component of the intervertebral disc, responsible for distributing hydraulic pressure and providing flexibility to the spine (NIH, 2021). Degenerating intervertebral disc nucleus pulposus tissue represents a pathological state where the balance between extracellular matrix (ECM) synthesis and degradation is disrupted, often leading to chronic low back pain and structural disc failure (Frontiers in Pharmacology, 2025). This degeneration is driven by the upregulation of matrix metalloproteinases (MMPs) and ADAMTS enzymes, alongside increased levels of pro-inflammatory cytokines like IL-1β and TNF-α (ResearchGate, 2021). Additionally, the accumulation of senescent cells within the NP tissue contributes to a catabolic microenvironment through the secretion of senescence-associated secretory phenotype (SASP) factors (Nature Communications, 2021). Therapeutic strategies targeting this tissue include the use of senolytic drugs like dasatinib and quercetin to remove aged cells, as well as regenerative approaches using mesenchymal stem cells to restore the functional NPC population (NIH, 2026). However, the avascular nature of the NP tissue presents significant challenges for drug delivery and sustained therapeutic efficacy (PubMed, 2015).

Other names

Degenerated nucleus pulposusIDD tissueNucleus pulposus of degenerated discDegenerating NP tissue

Therapeutic interventions targeting degenerating nucleus pulposus tissue primarily utilize senolysis to eliminate senescent cells, inhibition of matrix-degrading enzymes (MMPs and ADAMTS) to prevent ECM breakdown, and the delivery of growth factors or stem cells to stimulate the synthesis of aggrecan and type II collagen.